2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jeanne M. Palmer, MD, discusses the current treatment landscape of acute graft-versus-host disease.
Jeanne M. Palmer, MD, a hematologist and oncologist in the Department of Hematology and Bone Marrow Transplant Program at Mayo Clinic, discusses the current treatment landscape of acute graft-versus-host disease (aGVHD).
Steroids, such as methylprednisolone or prednisone, remain the mainstay of first-line treatment for patients with aGVHD treatment, says Palmer.
At the start of treatment, patients typically receive a steroid dose of 0.50 mg/kg to 2 mg/kg, says Palmer. As long as patients are responding, the dose is typically decreased over time.
Patients who do not have an adequate response after 3 to 5 days of treatment are considered steroid refractory, Palmer adds.
Several second-line treatment options are available to treat patients with steroid-refractory disease. However, there are no robust data to indicate which option is superior, says Palmer.
Finally, it is critical to remember that data from single-center studies may not be as compelling as multi-center studies, Palmer concludes.